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Variation in surfactant protein D (SP-D) is associated with lung
function in tobacco smoke-induced chronic respiratory disease. We
hypothesized that the same association exists in the general population
and could be used to identify individuals sensitive to smoke-induced
lung damage. The association between serum SP-D (sSP-D) and
expiratory lung function was assessed in a cross-sectional design in a
Danish twin population (n  1,512, 18–72 yr old). The adjusted
heritability estimates for expiratory lung function, associations be-
tween SP-D gene (SFTPD) single-nucleotide polymorphisms or hap-
lotypes, and expiratory lung function were assessed using twin study
methodology and mixed-effects models. Significant inverse associa-
tions were evident between sSP-D and the forced expiratory volume
in 1 s and forced vital capacity in the presence of current tobacco
smoking but not in nonsmokers. The two SFTPD single-nucleotide
polymorphisms, rs1923536 and rs721917, and haplotypes, including
these single-nucleotide polymorphisms or rs2243539, were inversely
associated with expiratory lung function in interaction with smoking.
In conclusion, SP-D is phenotypically and genetically associated with
lung function measures in interaction with tobacco smoking. The
obtained data suggest sSP-D as a candidate biomarker in risk assess-
ments for subclinical tobacco smoke-induced lung damage. The data
and derived conclusion warrant confirmation in a longitudinal popu-
lation following chronic obstructive pulmonary disease initiation and
development.
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SURFACTANT PROTEIN D (SP-D) levels in bronchoalveolar lavage
fluid (BALF) and serum SP-D (sSP-D) are suggested biomark-
ers for pulmonary injury in a variety of respiratory diseases,
and sSP-D is associated with mortality (23, 30, 33). The
chronic lung inflammation, such as appears after long-term
tobacco smoking, is assumed to alter the permeability of the
lung-blood barrier (17), thereby allowing the passage of SP-D
from the pulmonary compartment to the circulation. Tobacco
smoking has been shown to be associated with decreased SP-D
levels in BALF as well as with increased levels of sSP-D,
indicating protein leakage to the circulation from inflamed
lungs (22, 29, 32).
A decrease in sSP-D after steroid treatment was found in the
Evaluation of COPD Longitudinally to Identify Predictive Surro-
gate Endpoints (ECLIPSE) multi-center study, which investigated
patients with chronic obstructive pulmonary disease (COPD), and
sSP-D was correlated with symptom relief (9). Similar findings
were obtained in a randomized placebo-controlled study, in addi-
tion to alterations in the forced expiratory volume in 1 s in
percentage of that predicted (FEV1%pred) (28). In additional
studies of advanced patients, sSP-D was associated to exacerba-
tions (21) and loss of lung density (5). However, few studies have
evaluated sSP-D associations in individuals with subclinical phe-
notypes and “at risk” individuals and the role of tobacco smoking.
Several single-nucleotide polymorphisms (SNPs) in the
SP-D gene (SFTPD; 10q22.2-q23.1) are associated with sSP-D
(9, 29). Three SFTPD SNPs (including rs721917, a Met11Thr
variation) were further associated with FEV1%pred in stable
COPD (9), whereas five SNPs were associated with increased
risk of COPD development in a genome-wide association study
(18). Moreover, rs721917 is reported to have a significant asso-
ciation with both lung cancer and with emphysema (13–15).
Tobacco smoking is considered to be the major environmen-
tal risk factor for lung function decline and COPD. Neverthe-
less, tobacco smoking only accounts for15% of the variation
in lung function (4), and the subgroup of smokers who are
susceptible to developing persistent airway inflammation re-
mains unclearly characterized.
In the present study, we sought to test the hypotheses that
sSP-D could serve as a proxy for smoke-induced preclinical
pulmonary damage associated with lung function measures and
that SFTPD variants contribute to the genetic variation in lung
function in the general population. We used twin methodology
and a mixed-effects model framework to determine these
associations. Our data support that sSP-D may serve as bio-
marker in smokers and not in nonsmokers.
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MATERIALS AND METHODS
Ethical considerations. Written informed consent was obtained
from all twins, and the study was conducted according to the Helsinki
declaration. The study was approved the Regional Scientific Ethical
Committee for Southern Denmark, who briefed other regional and
national committees because of the nationwide nature of the study.
Study population. The study population included participants in
GEMINAKAR, a nationwide Danish twin study previously described
in detail (3, 27). A total of 756 twin pairs, 309 monozygotic, 316
same-sex dizygotic, and 131 opposite-sex dizygotic twins, underwent
full-day examinations from 1997 to 2000.
Lung function testing, blood sample collection, and sSP-D analysis.
Forced spirometry was conducted by trained study nurses on both
twins on the same day at two different investigational centers, accord-
ing to the most recent guidelines at that time (2). Spirometry was
performed using a Vitalograph dry-bellow spirometer in Copenhagen
and a noncommercial pneumotachograph in Odense. Prior or present
medical history of respiratory disease, registration of current medica-
tions, information regarding tobacco smoking status, and prior to-
bacco smoking history were obtained by questionnaire. Blood samples
were drawn the same day and stored at 80°C until analysis. sSP-D
was measured using a sandwich ELISA, as previously described (20).
Genotyping. Seven SNPs, rs1923534, rs1923536, rs12770776,
rs721917, rs17878336, rs2243639, and rs3088308, were selected for
genotyping, which was performed on 1,440 subjects using TaqMan
genotyping assays following the manufacturer’s recommendations
(Applied Biosystems, Foster City, CA) (Table 1). A schematic view of
the positions and linkage disequilibrium (LD) plot is depicted in Fig. 1.
The strongest linkage disequilibrium within SFTPD (Fig. 2) was
found between rs1923536 and rs721917 (r2  0.4).
Statistical analysis: analysis of association between phenotypic
continuous variables. A Box-Cox analysis was used to identify an
optimal normalizing transformation for the outcome variables. Fol-
lowing transformations were performed to achieve optimized distri-
bution for the outcome variables: sSP-D0.088, (FEV1)0.57, forced
vital capacity (FVC)0.31, FEV1/FVC2.21. When comparisons of con-
tinuous variables between the groups were made, t-test variances were
used for two-group comparisons, and a one-way ANOVA with Bon-
ferroni post hoc analysis was used for three-group comparisons. The
significant effects associated with outcome variables were estimated
using classical twin methodological variants of mixed-effects regres-
sion models, which also provides estimates of heritability, fitted using
the statistical tool (twinlm) in the Analysis of Multivariate Events
mets-package in R (ver.2.15) (11). The most parsimonious models
were chosen according to Akaike’s Information Criterion (AIC) (1),
aiming at minimizing AIC. Graphs illustrating associations between
sSP-D and FEV1 were created in predxcon, after adjustment for
covariates.
Analysis of genotype-phenotype association. SNPs were tested for
Hardy-Weinberg equilibrium using genhw command, based on chi2
test, in STATA (ver. 11). Linkage disequilibrium (LD) was evaluated
in Haploview (ver. 4.2). An analysis of the association between SNPs
and quantitative traits was performed using the most parsimonious
twin model from heritability analyses, as described above. The inter-
actions between SNPs and current tobacco smoking were further
tested.
The haplotypes were inferred using the 2SNP package with the
linear mixed-effects model implemented in the lmekin function in the
free R package kinship (31). With this model, we were able to
explicitly model the genetic relationship in monozygotic and dizy-
gotic twin pairs to assess haplotype associations. The haplotypes were
analyzed by a three-SNP sliding-window approach and by assuming
an additive effect. The regression model allows for the estimation of
the main effects and the interaction effects between haplotypes and
covariates.
Table 1. Single nucleotide polymorphism genotyping assay information
Assay Primers Reporters
RS17881954- RS17881954-YCF (f) RS17881954-YCV2
YC AGCTTGGAAAACCTATTTGAGGGAAT TTCTCTGGCAAGACC
(rs1923534) RS17881954-YCR (r) RS17881954-YCM2
TTCTCTGAGCATCTCCTATCTGGAT CTAATTCTCTAGCAAGACC
RS17881712- RS17881712-RCF (f) RS17881712-RCV1
RC GCTTGAGACCAGGAGTTTGAGA CCAGCATGGGCAAC
(rs1923536) RS17881712-RCR RS17881712-RCM1
(r)TGATCACACCTGGCTAATTTCTCTTTT CAGCGTGGGCAAC
RS17886375- RS17886375-YCF (f) RS17886375-YCV2
YC TTGGATAAAAGTAGCATCAGCTCAGG TCTTGTGCGCTGTTCT
(rs12770776) RS17886375-YCR (r) RS17886375-YCM2
CTGCCATCTTAGCTGGTGTTTG TCTTGTGCACTGTTCT
HSPD32- HSPD32-YCMTF (f) HSPD32-YCMTV2
YCMT CTGGAAGCAGAAATGAAGACCTACT ACTGGGCGTTGTTC
(rs721917) HSPD32-YCMTR(r) HSPD32-YCMTM2
CTACACATGACCAGGGTGCAA CTGGGCATTGTTC
RS17878336- RS17878336-SCVLF (f) RS17878336-SCVLV2
SCVL GTGTGCCTGGTCCAGCT CCCTGCTTCCCCACGG
(rs17878336) RS17878336-SCVLR(r) RS17878336-SCVLM2
CTTGCCCTGAGGTCCTATGTTC CCCTGCTTCCCCAGGG
RS2243639- RS2243639-YCATF RS2243639-YCATV1
YCAT CCAGCCCAGCTCTTTCCA CCCTGCGTTTCCA
(rs2243639) RS2243639-YCATR RS2243639-YCATM1
CTGGTGAGCGTGGAGTCC CCCCTGTGTTTCC
RS17884807- RS17884807-WCTSF (f) RS17884807-WCTSV1
WCTS ACAGCTGCTGTGCACACA ACAGTTGGCCACTCCA
(rs3088308) RS17884807-WCTSR (r) RS17884807-WCTSM1
TGCAAGGCGGCATTCTCA CAGTTGGCCTCTCCA
Assays were produced by Custom TaqMan Single-Nucleotide Polymorphism (SNP) Genotyping Assay Service, except for assay HSPD32-YCMT, which was
produced by Assays-by-Design (SM) Service. SNP Genotyping. f, forward primer; r, reverse primer.
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RESULTS
Association between sSP-D levels and expiratory lung func-
tion measures. sSP-D was measured in 1,476 of a total of 1,512
subjects; 20 subjects were excluded due to recent or ongoing
airway infection, which could potentially affect sSP-D and
forced expiratory lung function measures. Of these subjects,
1,355 had technically satisfactory measurements based on
forced spirometry. Fifty-seven subjects (4%) had self-reported
respiratory disease (asthma 55, emphysema 1, sarcoidosis
1). There was no significant difference in sSP-D in these
diseased subjects (1,142  635 ng/ml) relative to the residual
subjects in the cohort (1,111  637 ng/ml) (P  0.7).
The basic characteristics of all subjects, stratified by tobacco
smoking, are presented in Table 2. The sSP-D levels were
significantly higher in current tobacco smokers than in never-
smokers (P  0.0001) and ex-smokers (P  0.0001), whereas
the difference between the never-smokers and ex-smokers was
not significant (P  0.06).
No main effects in expiratory lung function were observed
by mixed-effects model with sSP-D as a response variable.
However, there was a significant negative association between
sSP-D and tobacco smoking and the interaction effects “current
tobacco smoking*FEV1” (P  0.0003), “current tobacco
smoking*FVC” (P  0.007), and “current tobacco smoking*
FEV1/FVC” (P  0.003). These associations remained signif-
icant after correction for “respiratory disease” (Table 3). Thus
sSP-D was inversely correlated with expiratory lung function
measures but only in smokers and not in nonsmokers. The
relative largest effect was that a 1-l decrease in FEV1 was
associated with a sSP-D increase of 141 ng/ml in smokers. The
relationships between sSP-D and FEV1, stratified by tobacco-
smoking status, are illustrated in Fig. 1.
Heritability of lung function. Data from intact twin pairs,
with both twins having reliable forced spirometry measure-
ments and neither twin affected by respiratory disease (chronic
or acute), were used for a heritability analysis. These subjects
included 269 monozygotic pairs, 266 same-sex dizygotic pairs,
and 106 opposite-sex dizygotic pairs. The best fitting model
was the additive genetic influences (A) and unique environ-
Fig. 1. Linkage disequilibrium (LD) plot of 7 single-nucleotide polymorphisms
(SNPs) in the 5= region and exons of the Surfactant Protein D gene (SFTPD).
Schematic view of the position and corresponding region of the mature protein.
Pairwise LD values displayed in r2.
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Fig. 2. Association between serum SP-D (sSP-D) and forced expiratory
volume in 1 s (FEV1). Data are stratified by tobacco smoking. A: current
smokers. B: ex-smokers. C: nonsmokers. The fitted, dotted line shows the
predicted linear association between sSP-D and FEV1. The dashed line shows
the 95% confidence interval (CI). The prediction, P value, and CI are estimated
from a multiple regression adjusted for age, height, weight, sex, pack-years,
respiratory disease, and investigation center, clustered in twin pairs.
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mental influences (E) (AE model) for both FEV1 and FVC. The
heritability estimate was h2  0.79 for FEV1 and h2  0.80 for
FVC (Table 4). The AE model decomposes the variances into
and suggests the variation in expiratory lung function predom-
inantly to be caused by additive genetic effects.
SFTPD SNP associations with sSP-D and lung function
measures. The frequencies of SNPs in the total number of
genotyped twin subjects (1,440) are presented in Table 5. All
SNPs were in Hardy-Weinberg disequilibrium, with the exception
of one SNP, rs2243639, which was close to Hardy-Weinberg
disequilibrium (estimated disequilibrium coefficient  0.01, P 
0.09).
The genetic association analysis using sSP-D as a response
variable revealed significant negative dosage effects of the
minor alleles of rs1923534, rs12770776, rs721917, and
rs3088308. There were positive dosage effects of rs17878336
and 1923536 (Table 6, Fig. 3, A–F). The figures show that
effects were similar in nonsmokers and smokers. In line with
this, interactions between SNPs and current smoking were not
significant, and an interaction effect was not included in the
statistical analyses of relations between SNPs and sSP-D as
shown in Table 6.
Analyses of the associations between SFTPD SNPs and
FEV1 (Table 6) revealed significant negative associations be-
tween rs1923536 and rs721917 in interaction with current
tobacco smoking and negative association with rs2243639
independently from smoking, whereas the association was
positive for rs1923534 (Fig. 4, A–D). Moreover, a negative
association was found between FVC and rs1923536 in inter-
action with current tobacco smoking (Table 6). The associa-
tions found for rs1923536 remained significant after correction
for multiple testings (Table 6). In short, these complex patterns
of associations showed that two SNPs located in the 5=-region
(rs1923534 and rs1923536) appeared to influence sSP-D and
expiratory lung function in inverse directions in smokers. In
contrast, the traditionally investigated coding SNP rs721917
(Met11Thr) appeared to influence sSP-D and expiratory lung
function in parallel directions in smokers.
Haplotype association between sSP-D and lung function
measures. Several haplotypes constructed from the three-SNP
sliding window analysis were associated with the sSP-D level
(Table 7). The direction of effects inferred from the SNP
association with sSP-D was repeated in the direction of the
effects from the haplotype analyses. The highest level of
significance for haplotype associations with sSP-D was found
for haplotypes including rs721917. The most significant hap-
lotype included the major alleles of rs1923536 and rs12770776
and minor allele of rs721917 (P  6.6e-27).
Several significant associations were found between SFTPD
haplotypes and FEV1 or FVC in interaction with smoking. The
highest degrees of significance were found for the associations
between FEV1 or FVC, with the haplotype including the major
allele of rs17878336 and minor alleles of rs721917 and
rs2243639 (P  0.003 and P  0.0007, respectively). This
haplotype (frequency  29%), which contained two structural
variant SNPs, inferred decreased sSP-D and also appeared to
decrease expiratory lung function in smokers.
DISCUSSION
The present study showed a significant inverse relation
between lung function and sSP-D in smokers. The results are in
agreement with previous findings from diseased cohorts,
whereby sSP-D was suggested to reflect smoke-induced in-
flammation in the lungs (21, 32). However, our observations
are obtained from a general population. Moreover, the present
findings indicate that genetic SP-D variations may influence
lung function in smokers in the general population.
There is some controversy regarding the association between
sSP-D levels and expiratory lung function in disease. Olesen et al.
(24) found an inverse correlation between sSP-D and FEV1 in
patients with cystic fibrosis. Contradictive results were found in
COPD, with no significant correlation between sSP-D and FEV1
in the ECLIPSE cohort (21) and in a Swedish mixed twin cohort
that included patients with COPD, smokers, and nonsmokers
(8). In contrast, Winkler et al. (32) reported significant corre-
lations.
Table 2. Basic characteristics of the total population
stratified by tobacco smoking
Smokers Ex-Smokers Never-Smokers
n  492 n  248 n  769
sSP-D, ng/ml 1187  968† 869  668 820  523
FEV1% 94  12† 100  13 99  12
FVC% 97  11† 102  12 100  11
FEV1/FVC% 78  7† 78  5* 80  6
Age, yr 38  11* 42  10† 36  11
Gender, % female 53 52 51
BMI, kg/m2 24  3 25  4* 24  4
Pack-years 12  17 6  12
Height, cm 173  9 173  9 173  10
Weight, kg 72  13 75  13 74  13
Serum surfactant protein D (sSP-D) and pack-years are presented as the
median  interquartile range; others are presented as the means  SD.
FEV1%, forced expiratory volume in 1 s in percent of that predicted; FVC,
forced vital capacity in percent of that predicted; BMI, body mass index. One
pack-year  20 cigarettes daily or 50 g tobacco weekly in one year. Compar-
ison analysis with 1-way ANOVA, with never-smokers as the reference group.
*P  0.05, †P  0.0005.
Table 3. Association analysis between lung function and sSP-D
FEV1 FVC FEV1/FVC
 (SE) P†/‡  (SE) P†/‡  (SE) P†/‡
Lung function, l 46 (39) ns/ns 25 (33) ns/ns 0.49 (3.5) ns/ns
Smoking 740 (144) e/d 626 (147) e/d 1320 (371) c/b
Smoking*lung function, l 141 (39) c/c 85 (31) b/b 14 (4.7) b/a
FEV1, FVC, and obstructive index FEV1/FVC associations with sSP-D. The -coefficients () (ng/ml) and SE of the mean result from a mixed-effect model
with sSP-D as a response variable. †P, nominal P value obtained using nontransformed values; ‡P, nominal P value obtained using transformed values.
Covariates: expiratory lung function, age, sex, current tobacco-smoking status, pack-years, height, weight, respiratory disease, investigation center, and “current
smoking *lung function” interaction. aP  0.05, bP  0.01, cP  0.001, dP  0.0001, eP  0.00001.
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In the present study, we found a negative association be-
tween sSP-D and expiratory lung function in smokers. The
relatively largest effect was that a 1-l decrease in FEV1 was
associated with a sSP-D increase of 141 ng/ml in smokers.
There was, however, no evident association in ex-smokers.
Because most COPD cohorts comprise both smokers and
ex-smokers/nonsmokers, this observation may putatively ex-
plain the lack of correlation in previous studies. Our observa-
tions support the general notion that sSP-D reflects inflamma-
tory lung damage but further suggest that it is acute tobacco
smoke-induced sSP-D that can serve as a significant lung
damage biomarker in the adult population without infection or
other severe pulmonary disease.
SNP and haplotype analyses have previously shown associ-
ations between SFTPD genotypes and COPD and associations
with the quantitative traits FEV1 and FVC. In particular,
rs721917 (Met11Thr), a variation in the NH2-terminal domain
of the SP-D molecule, is suggested to play a role in pulmonary
disease development and has been shown to influence oli-
gomerization, immunological function, and serum levels of the
molecule (9, 14, 15, 20). Consistent with previous studies, we
observed a negative association between sSP-D and the minor
allele of rs721917 (10). We also found a negative association
between the minor allele of rs721917 and lung function in the
smokers in this general population. However, we found a
stronger negative association with lung function for rs1923536,
an SNP located in the 5=-gene regulatory sequence; the pres-
ence of the minor allele of this SNP was associated with a
264-ml decrease in FVC in smokers. The statistical strength of
the association between SNPs and expiratory lung function
measures appeared weak but was comparable to the strength of
the association with COPD phenotypes in a previous study of
SFTPD variation (9).
Using SFTPD haplotype analysis, our findings paralleled
those of the SNP analysis with regard to associations with
sSP-D, and the observations represent a further extension of
the previously well-described high degree of genetic determi-
nation of sSP-D (29). The highest level of significance for a
SFTPD haplotype association with lung function was found for
one haplotype, including the minor alleles of rs721917 and one
additional structural polymorphism, rs2243639. This haplotype
had a frequency of 29% and was associated with a 100-ml
decrease in FVC in smokers.
Based on the relation between smoke-induced increases in
sSP-D and lowered lung function, it could be expected that
SNPs increasing sSP-D would infer decreases in lung function
and vice versa. However, cigarette smoke and pulmonary
disease will increase systemic SP-D irrespective of the SFTPD
genotype, although to different degrees according to the geno-
type.
However, both inverse and parallel relations between SNP/
sSP-D and SNP/lung function were found in this study. The
parallel associations seen for the coding SNP rs721917 are
partly in line with observations from Ishii et al. (15), who used
two small Japanese populations to demonstrate that subjects
with a minor allele at rs721917 are more susceptible to em-
physema investigated by high-resolution computed tomogra-
Table 4. Variance decomposition and heritability estimates of expiratory lung function
Variance Component A D C E h2 AIC ICC MZ ICC DZ
FEV1
AE 0.79 0.21 0.79 1551.2 0.79 0.39
ACE 0.79 9E-15 0.21 0.79 1549.2 0.79 0.32
ADE 0.48 0.31 0.21 0.79 1522.0 0.79 0.32
DE 0.79 0.21 0.79 1548.0 0.79 0.20
FVC
AE 0.80 0.20 0.80 3713.8 0.80 0.40
ACE 0.80 2E-10 0.20 0.80 3711.9 0.80 0.40
ADE 0.57 0.23 0.19 0.81 3713.6 0.81 0.34
DE 0.81 0.19 0.81 3707.1 0.81 0.20
A, additive genetic variance; D, nonadditive genetic variance; C, common environmental variance; E, individual environmental variance; h2, broad-sense
heritability; AIC, Aikakes information criteria; ICC, intraclass correlation; MZ, monozygotic; DZ, dizygotic. Covariates: age, sex, height, birth weight, current
tobacco-smoking status, pack-years, and investigation center.
Table 5. Frequencies of SFTPD single-nucleotide
polymorphisms
SNP Location Base Substitution (amino acid substitution) N(F)
rs1923534 TT 1243 (0.89)
5= region TC 153 (0.11)
CC 7 (0.005)
MAF (0.06)
rs1923536 GG 800 (0.58)
5=region GA 495 (0.36)
AA 90 (0.06)
MAF (0.24)
rs12770776 AA 1288 (0.91)
5= region AG 125 (0.09)
GG 3 (0.002)
MAF (0.05)
rs721917 TT (Met/Met) 496 (0.34)
exon 2 CT (Met/Thr) 685 (0.48)
CC (Thr/Thr) 259 (0.18)
MAF (0.42)
rs17878336 CC (Leu/Leu) 1319 (0.94)
exon 4 CG (Leu/Val) 89 (0.06)
GG (Val/Val) 4 (0.003)
MAF (0.03)
rs2243639 TT (Thr/Thr) 378 (0.27)
exon 5 TC (Thr/Ala) 674 (0.48)
CC (Ala/Ala) 360 (0.25)
MAF (0.49)
rs3088308 AA (Ser/Ser) 1254 (0.89)
exon 8 AT (Ser/Thr) 156 (0.11)
TT (Thr/Thr) 7 (0.005)
MAF (0.06)
N, numbers; F, frequency; MAF, minor allele frequency; Met, methionine;
Thr, threonine; Leu, leucine; Val, valine; Ala, alanine; Ser, serine.
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phy. A resembling relation was found in the NETT-NAS study,
where this minor allele of rs721917 was overrepresented in
COPD (9). The paradoxical pattern of association may imply
that it is genetically determined structural SP-D variation,
which affects the lung function rather than the genetically
determined level of sSP-D synthesis. Alternatively, the inves-
tigated SNPs may be linked to other genetic variation within or
outside SFTPD that determine expiratory lung function. The
level of significance for our haplotype analyses was higher than
the level of significance obtained using single-SNP analyses.
However, it was beyond the scope of the study to determine
whether the investigated SNPs were functional or markers of
other functional SNPs in neighboring genetic regions.
A fraction (4%) of the twins had self-reported respiratory
disease and thus cannot be classified with subclinical lung
damage. Estimations of the association between sSP-D and
expiratory lung function provided in Table 3 are, however,
corrected for the presence of respiratory disease by inclusion of
this covariate in the statistical analysis. Self-reported respira-
tory disease affected neither the association between SFTPD
variation and sSP-D nor between SFTPD variation and expi-
ratory lung function. As a sensitivity analysis, when those
Table 6. SFTPD single nucleotide polymorphism association analyses to sSP-D levels and expiratory lung function measures
sSP-D FEV1 FVC
Main Main Interaction Main Interaction
 P†/‡  P†/‡  P†/‡  P†/‡  P†/‡
rs1923534 200 e/e 25 ns/ns 90 ns/b 0.8 ns/ns 20 ns/ns
rs1923536 87 c/e 53a ns/ns 22 c/c 76 ns/ns 264 c/d
rs12770776 228 ns/d 7a ns/ns 21 ns/ns 77 ns/ns 120 ns/ns
rs721917 120 d/f 31 ns/ns 105 b/b 9 ns/ns 36 ns/ns
rs17878336 162 f/f 12a ns/ns 26g ns/ns 51g ns/ns 19g ns/ns
rs2243639 4 ns/ns 70a b/b 40 ns/ns 52 ns/ns 11 ns/ns
rs3088308 220 c/f 40 ns/ns 40 ns/ns 0.5 ns/ns 0.1 ns/ns
SNP associations to the quantitative traits sSP-D, FEV1, and/or FVC. Interaction effects were calculated for SNP and current tobacco smoking. Covariates:
sex, age, weight, height, tobacco smoking, SNP-current tobacco-smoking interaction. Main, main effects; Interaction, interaction effects; : -coefficient
resulting from analysis using nontransformed values (sSP-D: ng/ml, FEV1: ml, FVC: ml); †P, nominal P value obtained using nontransformed values; ‡P,
nominal P value obtained using transformed values. aRecessive model, bP  0.05, cP  0.01, dP  0.001, eP  0.0001, fP  0.00001, gdominant model.
Additional estimated -coefficients are calculated using an additive model.
o
rs3088308
 
rs721917
TT  TC  CC    TT  TC  CC GG GA AA     GG GA AA
AA  AG GG    AA  AG GG TT  TC  CC    TT  TC  CC
rs12770776
4,000
2,000
0s
SP
-D
 (n
g/m
l) 4,000
2,000
0s
SP
-D
 (n
g/m
l)
4,000
2,000
0s
SP
-D
 (n
g/m
l)
4,000
2,000
0s
SP
-D
 (n
g/m
l)
rs1923536
Non-smoker   Smoker Non-smoker   Smoker
sS
P-
D 
(ng
/m
l)
sS
P-
D 
(ng
/m
l)
AA  AT  TT     AA  AT  TT
4,000
2,000
0
BA
DC
FE
4,000
2,000
0
rs17878336
CC CG GG    CC CG GG
rs1923534
Fig. 3. Effect of SFTPD SNPs on sSP-D. The observations
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tution. A: rs1923534. B: rs1923536. C: rs12770776.
D: rs721917. E: rs17878336. F: rs3088308.
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subjects with self-reported lung disease were excluded, we
obtained similar results.
Due to the nature of the study, we were able to determine the
heritability of lung function. We have previously determined
sSP-D heritability as h2  0.83 (29). We also found high
heritability estimates, 0.79 for FEV1 and 0.80 for FVC, in the
present investigation. Other twin studies have shown varying
adjusted heritability estimates of FEV1 and FVC in adults,
ranging from 0.3 to 0.9 (12, 25). In accordance with a previous
Danish twin study (13), we found that the best explanatory
model for FEV1 variation included additive genetic effects and
individual environmental effects.
The strength of this study was the large number of investi-
gated subjects, allowing for the analysis of subgroups within
the study population. We were also able to investigate the
variation in lung function in individuals without evident dis-
ease. Most pulmonary biomarker studies to date have exam-
ined cohorts with advanced respiratory diseases, with the
biomarkers likely reflecting events within the established dis-
ease, such as exacerbations or comorbidities, rather than the
propensity for disease development. There are also shortcom-
ings of this study. Only tobacco smoking was available as a
descriptor for environmental exposure, and the study was not
designed to identify additional SNP variations within SFTPD,
flanking regions, or neighboring genes, which may contribute
to the observed genotype-trait associations. Moreover, due to
the cross-sectional design, we were not able to elucidate
whether the associations between sSP-D and lung function can
predict future clinical disease states.
The most important limitation in relying on lung function
only in COPD prognosis is that lung function is a remarkably
poor predictor of disease activity; it is impossible to know from
measures of lung function whether the underlying inflamma-
tion is aggressive or still ongoing. Our data show that both
sSP-D and expiratory lung function measures are reversible to
a normal state in ex-smokers, supporting the notion that sSP-D
may serve as biomarker in smokers and not in ex-smokers.
Other studies have demonstrated that sSP-D is increased in
advanced smoke-induced disease with association to exacerba-
tions (21) but also significantly associated with baseline lung
density and its decline over time (5). On that basis, we suggest
that sSP-D likewise may reflect inflammatory events essential
in COPD initiation.
Surrogate markers capable of reflecting early changes in
smoke-induced pathology may be beneficial for the early
identification of individuals “at risk” of developing COPD
(19), and sSP-D has the potential to serve as an indicator of
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D: rs2243639.
Table 7. Three-SNP sliding window haplotype associations to sSP-D levels and expiratory lung function measures
sSP-D FEV1 FVC
Main Main Interaction Main Interaction
rs1923534 rs1923536 rs12770776 rs721917 rs17878336 rs2243539 rs3088308 Freq  P†/‡  P†/‡  P†/‡  P†/‡  P†/‡
0 0 0 0.66 27 ns/ns 40 ns/ns 60 ns/a 20 ns/ns 70 ns/b
0 0 1 0.043 218 c/d 90 ns/ns 80 ns/ns 100 ns/ns 20 ns/ns
0 1 0 0.24 58 ns/c 40 ns/ns 80 a/a 8 ns/ns 60 ns/a
1 0 0 0.056 191 c/e 20 ns/ns 60 ns/ns 6 ns/ns 10 ns/ns
0 0 0 0.59 120 e/e 1 ns/ns 10 ns/a 8 ns/ns 70 a/b
0 0 1 0.13 293 e/e 50 ns/ns 10 ns/ns 20 ns/ns 30 ns/ns
0 1 1 0.042 220 b/e 80 ns/ns 60 ns/ns 100 ns/ns 200 ns/ns
1 0 1 0.23 61 a/c 30 ns/ns 70 ns/a 2 ns/ns 50 ns/a
0 0 0 0.57 87 c/c 1 ns/ns 10 ns/ns 3 ns/ns 20 ns/ns
0 1 0 0.36 85 b/c 3 ns/ns 50 ns/a 10 ns/ns 50 ns/a
1 1 0 0.04 220 b/e 80 ns/ns 60 ns/ns 100 ns/ns 200 ns/ns
0 0 0 0.40 24 ns/ns 30 ns/ns 60 ns/ns 20 ns/ns 50 ns/ns
0 0 1 0.16 84 b/c 40 ns/ns 20 ns/ns 30 ns/ns 5 ns/ns
1 0 0 0.11 65 a/ns 10 ns/ns 70 ns/ns 20 ns/ns 70 ns/ns
1 0 1 0.29 90 b/e 20 ns/ns 100 b/b 20 ns/a 100 b/c
0 0 0 0.49 5 ns/ns 20 ns/ns 80 a/a 4 ns/ns 80 ns/ns
0 1 0 0.42 9 ns/ns 3 ns/ns 100 b/b 2 ns/ns 90 a/b
Only haplotypes with a frequency (Freq.) 4%, are shown and analyzed for associations to the quantitative traits serum Surfactant Protein D (sSP-D), forced
expiratory volume in 1 s (FEV1), and/or forced vital capacity (FVC). 0: major allele, 1: minor allele. Interaction effects were calculated for haplotypes and current
tobacco smoking. Covariates: sex, age, weight, height, tobacco smoking, haplotype-current tobacco smoking interaction. Main: Main effects, Interaction:
interaction effects, : -coefficient resulting from analysis using nontransformed values (sSP-D: ng/ml, FEV1: mL, FVC: mL), p †: nominal P value obtained
using nontransformed values, p ‡: nominal P value obtained using transformed values. aP  0.05, bP  0.01, cP  0.001, dP  0.0001, eP  0.00001.
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COPD susceptibility in active tobacco-smoking individuals.
Current guidelines recommend against the spirometric screen-
ing of asymptomatic individuals, regardless of COPD risk
factors (26). These recommendations are based on the lack of
evidence for beneficial pharmacotherapy to treat asymptomatic
persons with or without airflow obstruction; thus, screening for
“persons at risk” using surrogate markers could be a futile
effort. However, recent reports have indicated that pharmaco-
therapies can improve symptoms, exacerbation frequency, rate
of FEV1 decline, and mortality in individuals with mild and
moderate COPD (6, 7, 16). On this basis, the identification of
persons at risk may enable early intervention with pharmacolog-
ical treatment in addition to the recommendation of tobacco-
smoking cessation.
In summary, the present findings suggest that sSP-D can
serve as a biomarker for subclinical inflammatory lung damage
in smokers in the general population. We further found that
genetic variations in SFTPD were associated with lower lung
function in interaction with smoking and thereby may affect
obstructive disease development. Longitudinal studies are war-
ranted to validate whether sSP-D measurements provide infor-
mation complementary to spirometric measures in the identi-
fication of persons at high risk of developing smoking-induced
COPD.
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